Neumora Therapeutics Inc.... (NMRA)
1.71
0.05 (3.01%)
At close: Feb 20, 2025, 3:59 PM
1.66
-2.56%
After-hours: Feb 20, 2025, 05:55 PM EST
undefined% (undefined)
| Bid | 1.65 |
| Market Cap | 275.46M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.2 |
| PE Ratio (ttm) | -1.42 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.71 |
| Volume | 1,066,000 |
| Avg. Volume (20D) | 3,175,335 |
| Open | 1.65 |
| Previous Close | 1.66 |
| Day's Range | 1.61 - 1.72 |
| 52-Week Range | 1.60 - 21.00 |
| Beta | undefined |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in pa...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 109
Stock Exchange NASDAQ
Ticker Symbol NMRA
Website https://www.neumoratx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NMRA stock is "Buy." The 12-month stock price forecast is $21.5, which is an increase of 1161.00% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
1 month ago
+14.29%
Neumora Therapeutics shares are trading higher. B ...
Unlock content with
Pro Subscription
1 month ago
-81.42%
Neumora Therapeutics shares are trading lower after the company announced its Phase 3 KOASTAL study did not demonstrate statistically significant improvement on its primary endpoint.
